Pricing and Reimbursement

The Economics of Drug Development in 2022 On 8 October, 2012, in celebration of its 50th anniversary, OHE will be holding an important conference to consider what drug development may look like ten years hence, in 2022. The conference will be held in London on Monday, 8 October 2012.

OHE’s Adrian Towse is co-author on the recent report by the ISPOR Good Research Practices Task Force on assessing comparative effectiveness using prospective observational studies.

Just out is an OHE Research Paper that examines the issues. The authors note that diagnostics not only facilitate health gain and cost savings, but also provide information to inform patients’ decisions on interventions and to clarify how their behaviour may affect their health in future.

Every year, OHE sponsors a lecture by an eminent economist or clinician that addresses an important current issue.

OHE's Dr Jorge Mestre-Ferrandiz is a visiting lecturer in the Department of Economics at City University London. As part of his 2012 activities, he recently gave a comprehensive lecture on the economics of the market for medicines in the UK.

Interest is growing in schemes that involve “paying for pills by results”, that is, “paying for performance” rather than merely “paying for pills”. Despite its intuitive appeal, this approach is is highly controversial and is disliked by many health care providers, policy makers, and pharmaceutical companies.

In a recent editorial in the European Journal of Health Economics, Prof Michael Drummond of York University and Prof Adrian Towse of the OHE take a new look at an old issue: the appropriate role of co-payments in health care.

During the last quarter of 2011, OHE team members were involved in discussions and presentations in a range of forums, covering each of OHE's three areas of focus. This post reviews their activities.

Join OHE for two exciting seminars, one on MCDA and the other on shifts in investment in R&D.

Antibacterial drug resistance is a serious and growing worldwide problem that threatens our ability to cure traditionally treatable diseases and to successfully perform numerous surgical procedures that rely on antibacterials. The current situation is due primarily to two causes: inappropriate use in humans and animals, and the decline in the development of new antibacterials, largely because of lower returns on investment in R&D. OHE has been very involved in both defining the challenge and thinking through possible responses.

Pages

Subscribe to RSS - Pricing and Reimbursement